Cellectis ADR (CLLS): Next-Year EPS Estimate 25.34%
As of 2026-07-02, Cellectis ADR (CLLS) has a next-year EPS growth estimate of 25.34%.
CLLS was first flagged by our screen on 2026-06-29 with a next-year EPS growth estimate of 25.34%. Current-year growth is projected at -32.96%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.34%
- EPS growth this year
- -32.96%
- EPS next quarter (est)
- -$0.26
- Last price
- $3.25
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-02 | 25.34% | -32.96% | -$0.26 | $3.25 |
| 2026-07-01 | 25.34% | -32.96% | -$0.26 | $2.94 |
| 2026-06-30 | 25.34% | -32.96% | -$0.26 | $3.00 |
| 2026-06-29 | 25.34% | -32.96% | -$0.26 | $2.94 |
Screen Performance
Aggregate stats across all 1829 tickers our top-EPS-revision screen has flagged over the past 92 days.
- Median return since detection
- +5.3%
- % of tickers in the green
- 59%
- Median return on winners
- +20.7%
- Large revisions captured
- 932
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Cellectis ADR's next-year EPS growth estimate?▾
As of 2026-07-02, Cellectis ADR (CLLS) has a next-year EPS growth estimate of 25.34%, based on analyst consensus.
What sector and industry does Cellectis ADR belong to?▾
Cellectis ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CLLS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Cellectis ADR (CLLS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports